Back

Skyhawk reports 1.59-point cUHDRS benefit for SKY-0515 in Huntington’s study

Verifying
  • Skyhawk reported final 15-month Phase 1/2 results for oral SKY-0515 in Huntington’s disease.
  • SKY-0515 produced a 1.59-point cUHDRS treatment difference versus external control at Month 15.
  • The Phase 1/2 study is complete, while FALCON-HD 004-WW continues recruiting worldwide.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.